{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T03:10:14Z","timestamp":1788318614063,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neuropathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Recently, conceptual systems for the in vivo staging of Alzheimer\u2019s disease (AD) using fluid biomarkers have been suggested. Thus, it is important to assess whether available fluid biomarkers can successfully stage AD into clinically and biologically relevant categories. In the TRIAD cohort, we explored whether p-tau217, p-tau205 and NTA-tau (biomarkers of early, intermediate and late AD pathology, respectively) have potential for biofluid-based staging in cerebrospinal fluid (CSF;\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009219) and plasma (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u2009150), and compared them in a paired CSF and plasma subset (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200976). Our findings suggest a good concordance between biofluid staging and underlying pathology when classifying amyloid-positivity into three categories based on neurofibrillary pathology: minimal\/non-existent (p-tau217 positive), early-to-intermediate (p-tau217 and p-tau205 positivity), and advanced tau tangle deposition (p-tau217, p-tau205 and NTA-tau positive), as indexed by tau-PET. Discordant cases accounted for 4.6% and 13.3% of all CSF and plasma measurements respectively (9.2% and 11.8% in paired samples). Notably, CSF- and plasma-based staging matched one another in 61.7% of the cases, while approximately 32% of the remaining participants were one to three biofluid stages higher in CSF as compared to plasma. Overall, these exploratory results suggest that biofluid staging of AD holds potential for offering valuable insights into underlying AD hallmarks and disease severity. However, its applicability beyond molecular characterization at research settings has yet to be demonstrated.\n                  <\/jats:p>","DOI":"10.1007\/s00401-025-02863-w","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:28:34Z","timestamp":1742174914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Biofluid-based staging of Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"149","author":[{"given":"Juan","family":"Lantero-Rodriguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia","family":"Montoliu-Gaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Pola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wagner S.","family":"Brum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guglielmo","family":"Di Molfetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Klostranec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime","family":"Montembeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecile","family":"Tissot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur C.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Jeromin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Gobom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"2863_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103836","volume":"76","author":"NJ Ashton","year":"2022","unstructured":"Ashton NJ, Benedet AL, Pascoal TA, Karikari TK, Lantero-Rodriguez J, Brum WS et al (2022) Cerebrospinal fluid p-tau231 as an early indicator of emerging pathology in Alzheimer\u2019s disease. EBioMedicine 76:103836. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103836","journal-title":"EBioMedicine"},{"key":"2863_CR2","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barthelemy","year":"2020","unstructured":"Barthelemy NR, Li Y, Joseph-Mathurin N, Gordon BA, Hassenstab J, Benzinger TLS et al (2020) A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat Med 26:398\u2013407. https:\/\/doi.org\/10.1038\/s41591-020-0781-z","journal-title":"Nat Med"},{"key":"2863_CR3","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/s43587-023-00380-7","volume":"3","author":"NR Barthelemy","year":"2023","unstructured":"Barthelemy NR, Saef B, Li Y, Gordon BA, He Y, Horie K et al (2023) CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer\u2019s disease. Nat Aging 3:391\u2013401. https:\/\/doi.org\/10.1038\/s43587-023-00380-7","journal-title":"Nat Aging"},{"key":"2863_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1038\/s41591-024-02869-z","volume":"30","author":"NR Barthelemy","year":"2024","unstructured":"Barthelemy NR, Salvado G, Schindler SE, He Y, Janelidze S, Collij LE et al (2024) Highly accurate blood test for Alzheimer\u2019s disease is similar or superior to clinical cerebrospinal fluid tests. Nat Med 30:1085\u20131095. https:\/\/doi.org\/10.1038\/s41591-024-02869-z","journal-title":"Nat Med"},{"key":"2863_CR5","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/alz.13518","volume":"20","author":"WS Brum","year":"2024","unstructured":"Brum WS, Ashton NJ, Simren J, di Molfetta G, Karikari TK, Benedet AL et al (2024) Biological variation estimates of Alzheimer\u2019s disease plasma biomarkers in healthy individuals. Alzheimers Dement 20:1284\u20131297. https:\/\/doi.org\/10.1002\/alz.13518","journal-title":"Alzheimers Dement"},{"key":"2863_CR6","unstructured":"C P (2018) World Alzheimer report 2018. The state of the art of dementia research: new frontiers. https:\/\/www.alzint.org\/resource\/world\u2010alzheimer\u2010report\u20102018\/. World Alzheimer Report:"},{"key":"2863_CR7","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jalz.2018.09.010","volume":"15","author":"Z Chen","year":"2019","unstructured":"Chen Z, Mengel D, Keshavan A, Rissman RA, Billinton A, Perkinton M et al (2019) Learnings about the complexity of extracellular tau aid development of a blood-based screen for Alzheimer\u2019s disease. Alzheimers Dement 15:487\u2013496. https:\/\/doi.org\/10.1016\/j.jalz.2018.09.010","journal-title":"Alzheimers Dement"},{"key":"2863_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1474-4422(18)30403-4","volume":"18","author":"GBDD Collaborators","year":"2019","unstructured":"Collaborators GBDD (2019) Global, regional, and national burden of Alzheimer\u2019s disease and other dementias, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:88\u2013106. https:\/\/doi.org\/10.1016\/S1474-4422(18)30403-4","journal-title":"Lancet Neurol"},{"key":"2863_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13024-019-0333-5","volume":"14","author":"MA DeTure","year":"2019","unstructured":"DeTure MA, Dickson DW (2019) The neuropathological diagnosis of Alzheimer\u2019s disease. Mol Neurodegener 14:32. https:\/\/doi.org\/10.1186\/s13024-019-0333-5","journal-title":"Mol Neurodegener"},{"key":"2863_CR10","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","volume":"29","author":"K Horie","year":"2023","unstructured":"Horie K, Salvado G, Barthelemy NR, Janelidze S, Li Y, He Y et al (2023) CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer\u2019s disease. Nat Med 29:1954\u20131963. https:\/\/doi.org\/10.1038\/s41591-023-02443-z","journal-title":"Nat Med"},{"key":"2863_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement 8:1\u201313. https:\/\/doi.org\/10.1016\/j.jalz.2011.10.007","journal-title":"Alzheimers Dement"},{"key":"2863_CR12","doi-asserted-by":"publisher","unstructured":"Jack CR Jr, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup. Alzheimers Dement: https:\/\/doi.org\/10.1002\/alz.13859","DOI":"10.1002\/alz.13859"},{"key":"2863_CR13","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.1038\/s41591-024-02988-7","volume":"30","author":"CR Jack Jr","year":"2024","unstructured":"Jack CR Jr, Andrews SJ, Beach TG, Buracchio T, Dunn B, Graf A et al (2024) Revised criteria for the diagnosis and staging of Alzheimer\u2019s disease. Nat Med 30:2121\u20132124. https:\/\/doi.org\/10.1038\/s41591-024-02988-7","journal-title":"Nat Med"},{"key":"2863_CR14","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB et al (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14:535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"key":"2863_CR15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R, Strandberg O, Proctor NK, Dage JL et al (2021) Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol 78:149\u2013156. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201","journal-title":"JAMA Neurol"},{"key":"2863_CR16","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41582-022-00665-2","volume":"18","author":"TK Karikari","year":"2022","unstructured":"Karikari TK, Ashton NJ, Brinkmalm G, Brum WS, Benedet AL, Montoliu-Gaya L et al (2022) Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol 18:400\u2013418. https:\/\/doi.org\/10.1038\/s41582-022-00665-2","journal-title":"Nat Rev Neurol"},{"key":"2863_CR17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s00401-023-02659-w","volume":"147","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, Montoliu-Gaya L, Benedet AL, Vrillon A, Dumurgier J, Cognat E et al (2024) CSF p-tau205: a biomarker of tau pathology in Alzheimer\u2019s disease. Acta Neuropathol 147:12. https:\/\/doi.org\/10.1007\/s00401-023-02659-w","journal-title":"Acta Neuropathol"},{"key":"2863_CR18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13024-024-00707-x","volume":"19","author":"J Lantero-Rodriguez","year":"2024","unstructured":"Lantero-Rodriguez J, Salvado G, Snellman A, Montoliu-Gaya L, Brum WS, Benedet AL et al (2024) Plasma N-terminal containing tau fragments (NTA-tau): a biomarker of tau deposition in Alzheimer\u2019s Disease. Mol Neurodegener 19:19. https:\/\/doi.org\/10.1186\/s13024-024-00707-x","journal-title":"Mol Neurodegener"},{"key":"2863_CR19","doi-asserted-by":"publisher","first-page":"5343","DOI":"10.1002\/alz.13119","volume":"19","author":"J Lantero-Rodriguez","year":"2023","unstructured":"Lantero-Rodriguez J, Tissot C, Snellman A, Servaes S, Benedet AL, Rahmouni N et al (2023) Plasma and CSF concentrations of N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimers Dement 19:5343\u20135354. https:\/\/doi.org\/10.1002\/alz.13119","journal-title":"Alzheimers Dement"},{"key":"2863_CR20","doi-asserted-by":"publisher","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O et al (2020) Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. Sci Adv 6: eaaz2387 https:\/\/doi.org\/10.1126\/sciadv.aaz2387","DOI":"10.1126\/sciadv.aaz2387"},{"key":"2863_CR21","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ, Smith R, Stomrud E, Serrano GE et al (2021) Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 13:e14022. https:\/\/doi.org\/10.15252\/emmm.202114022","journal-title":"EMBO Mol Med"},{"key":"2863_CR22","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S, Cullen N, Svenningsson AL, Strandberg O et al (2020) Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143:3234\u20133241. https:\/\/doi.org\/10.1093\/brain\/awaa286","journal-title":"Brain"},{"key":"2863_CR23","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00401-023-02660-3","volume":"147","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, Alosco ML, Yhang E, Tripodis Y, Sconzo D, Ally M et al (2023) Optimal blood tau species for the detection of Alzheimer\u2019s disease neuropathology: an immunoprecipitation mass spectrometry and autopsy study. Acta Neuropathol 147:5. https:\/\/doi.org\/10.1007\/s00401-023-02660-3","journal-title":"Acta Neuropathol"},{"key":"2863_CR24","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s43587-023-00405-1","volume":"3","author":"L Montoliu-Gaya","year":"2023","unstructured":"Montoliu-Gaya L, Benedet AL, Tissot C, Vrillon A, Ashton NJ, Brum WS et al (2023) Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. Nat Aging 3:661\u2013669. https:\/\/doi.org\/10.1038\/s43587-023-00405-1","journal-title":"Nat Aging"},{"key":"2863_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","volume":"71","author":"PT Nelson","year":"2012","unstructured":"Nelson PT, Alafuzoff I, Bigio EH, Bouras C, Braak H, Cairns NJ et al (2012) Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol 71:362\u2013381. https:\/\/doi.org\/10.1097\/NEN.0b013e31825018f7","journal-title":"J Neuropathol Exp Neurol"},{"key":"2863_CR26","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, Zetterberg H, Lopera F, Stomrud E et al (2020) Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA 324:772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"2863_CR27","doi-asserted-by":"publisher","first-page":"3517","DOI":"10.1093\/brain\/awab248","volume":"144","author":"TA Pascoal","year":"2021","unstructured":"Pascoal TA, Benedet AL, Tudorascu DL, Therriault J, Mathotaarachchi S, Savard M et al (2021) Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages. Brain 144:3517\u20133528. https:\/\/doi.org\/10.1093\/brain\/awab248","journal-title":"Brain"},{"key":"2863_CR28","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal TA, Therriault J, Benedet AL, Savard M, Lussier FZ, Chamoun M et al (2020) 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143:2818\u20132830. https:\/\/doi.org\/10.1093\/brain\/awaa180","journal-title":"Brain"},{"key":"2863_CR29","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1002\/alz.12801","volume":"19","author":"C Rabe","year":"2023","unstructured":"Rabe C, Bittner T, Jethwa A, Suridjan I, Manuilova E, Friesenhahn M et al (2023) Clinical performance and robustness evaluation of plasma amyloid-beta(42\/40) prescreening. Alzheimers Dement 19:1393\u20131402. https:\/\/doi.org\/10.1002\/alz.12801","journal-title":"Alzheimers Dement"},{"key":"2863_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s43587-024-00599-y","volume":"4","author":"G Salvado","year":"2024","unstructured":"Salvado G, Horie K, Barthelemy NR, Vogel JW, Pichet Binette A, Chen CD et al (2024) Disease staging of Alzheimer\u2019s disease using a CSF-based biomarker model. Nat Aging 4:694\u2013708. https:\/\/doi.org\/10.1038\/s43587-024-00599-y","journal-title":"Nat Aging"},{"key":"2863_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202217123","volume":"15","author":"G Salvado","year":"2023","unstructured":"Salvado G, Ossenkoppele R, Ashton NJ, Beach TG, Serrano GE, Reiman EM et al (2023) Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med 15:e17123. https:\/\/doi.org\/10.15252\/emmm.202217123","journal-title":"EMBO Mol Med"},{"key":"2863_CR32","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1093\/jnen\/nlw026","volume":"75","author":"A Serrano-Pozo","year":"2016","unstructured":"Serrano-Pozo A, Qian J, Muzikansky A, Monsell SE, Montine TJ, Frosch MP et al (2016) Thal Amyloid Stages Do Not Significantly Impact the Correlation Between Neuropathological Change and Cognition in the Alzheimer Disease Continuum. J Neuropathol Exp Neurol 75:516\u2013526. https:\/\/doi.org\/10.1093\/jnen\/nlw026","journal-title":"J Neuropathol Exp Neurol"},{"key":"2863_CR33","doi-asserted-by":"publisher","first-page":"2834","DOI":"10.1093\/brain\/awab481","volume":"145","author":"A Snellman","year":"2022","unstructured":"Snellman A, Lantero-Rodriguez J, Emersic A, Vrillon A, Karikari TK, Ashton NJ et al (2022) N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain 145:2834\u20132848. https:\/\/doi.org\/10.1093\/brain\/awab481","journal-title":"Brain"},{"key":"2863_CR34","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202012921","volume":"12","author":"M Suarez-Calvet","year":"2020","unstructured":"Suarez-Calvet M, Karikari TK, Ashton NJ, Lantero Rodriguez J, Mila-Aloma M, Gispert JD et al (2020) Novel tau biomarkers phosphorylated at T181, T217 or T231 rise in the initial stages of the preclinical Alzheimer\u2019s continuum when only subtle changes in Abeta pathology are detected. EMBO Mol Med 12:e12921. https:\/\/doi.org\/10.15252\/emmm.202012921","journal-title":"EMBO Mol Med"},{"key":"2863_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105046","volume":"102","author":"J Therriault","year":"2024","unstructured":"Therriault J, Ashton NJ, Pola I, Triana-Baltzer G, Brum WS, Di Molfetta G et al (2024) Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer\u2019s pathology. EBioMedicine 102:105046. https:\/\/doi.org\/10.1016\/j.ebiom.2024.105046","journal-title":"EBioMedicine"},{"key":"2863_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2967\/jnumed.120.245209","volume":"62","author":"J Therriault","year":"2021","unstructured":"Therriault J, Benedet AL, Pascoal TA, Savard M, Ashton NJ, Chamoun M et al (2021) Determining Amyloid-beta Positivity Using (18)F-AZD4694 PET Imaging. J Nucl Med 62:247\u2013252. https:\/\/doi.org\/10.2967\/jnumed.120.245209","journal-title":"J Nucl Med"},{"key":"2863_CR37","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000011416","volume":"96","author":"J Therriault","year":"2021","unstructured":"Therriault J, Pascoal TA, Benedet AL, Tissot C, Savard M, Chamoun M et al (2021) Frequency of Biologically Defined Alzheimer Disease in Relation to Age, Sex, APOE epsilon4, and Cognitive Impairment. Neurology 96:e975\u2013e985. https:\/\/doi.org\/10.1212\/WNL.0000000000011416","journal-title":"Neurology"},{"key":"2863_CR38","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","volume":"2","author":"J Therriault","year":"2022","unstructured":"Therriault J, Pascoal TA, Lussier FZ, Tissot C, Chamoun M, Bezgin G et al (2022) Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging. Nat Aging 2:526\u2013535. https:\/\/doi.org\/10.1038\/s43587-022-00204-0","journal-title":"Nat Aging"},{"key":"2863_CR39","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41582-024-00942-2","volume":"20","author":"J Therriault","year":"2024","unstructured":"Therriault J, Schindler SE, Salvado G, Pascoal TA, Benedet AL, Ashton NJ et al (2024) Biomarker-based staging of Alzheimer disease: rationale and clinical applications. Nat Rev Neurol 20:232\u2013244. https:\/\/doi.org\/10.1038\/s41582-024-00942-2","journal-title":"Nat Rev Neurol"},{"key":"2863_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1001\/jamaneurol.2022.4485","volume":"80","author":"J Therriault","year":"2023","unstructured":"Therriault J, Vermeiren M, Servaes S, Tissot C, Ashton NJ, Benedet AL et al (2023) Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol 80:188\u2013199. https:\/\/doi.org\/10.1001\/jamaneurol.2022.4485","journal-title":"JAMA Neurol"},{"key":"2863_CR41","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1002\/alz.13528","volume":"20","author":"MS Woo","year":"2024","unstructured":"Woo MS, Tissot C, Lantero-Rodriguez J, Snellman A, Therriault J, Rahmouni N et al (2024) Plasma pTau-217 and N-terminal tau (NTA) enhance sensitivity to identify tau PET positivity in amyloid-beta positive individuals. Alzheimers Dement 20:1166\u20131174. https:\/\/doi.org\/10.1002\/alz.13528","journal-title":"Alzheimers Dement"}],"container-title":["Acta Neuropathologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00401-025-02863-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00401-025-02863-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T01:28:38Z","timestamp":1742174918000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00401-025-02863-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["2863"],"URL":"https:\/\/doi.org\/10.1007\/s00401-025-02863-w","relation":{},"ISSN":["1432-0533"],"issn-type":[{"value":"1432-0533","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"KB has served as a consultant and at advisory boards for Acumen, ALZPath, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Novartis, Ono Pharma, Prothena, Roche Diagnostics, and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All participants or their legal relatives in case of severe dementia gave written informed consent to their participation in this study. Collection and analysis of samples were approved by the Research Ethics Board of the Douglas Mental Health Institute as well as the Faculty of Medicine Research Ethics Office, McGill University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}}],"article-number":"27"}}